

SenzaGen receives SEK 0.65 million order for in vitro skin allergy and irritation tests from global consumer product company

Lund, August 6, 2021

SenzaGen continues to receive orders from large global companies. A leading consumer product company has now entrusted SenzaGen to test product candidates during their product development phase. Valued at SEK 0.65 million, the project includes non-animal tests for both skin sensitization and skin irritation.

SenzaGen has started to collaborate with a global consumer product company with operations in several business areas and product groups. The company aims to use the combination of tests to evaluate whether product candidates may cause skin sensitization or irritation. Since July 1, 2021, SenzaGen's expanded service offerings include *in vitro* tests for skin irritation and corrosion, as a complement to the innovative GARD® platform with tests for skin and respiratory sensitization.

"It is promising that we already get orders for our new endpoint skin irritation. The order confirms the feedback we have received from customers, and our strategy to broaden our testing services by offering customers in our priority markets a wider range of tests within non-animal skin toxicology, in this case both skin sensitization and skin irritation", says Axel Sjöblad, CEO of SenzaGen.

Demand for contract research services for non-animal skin toxicological testing is continuously growing in SenzaGen's target markets, where the company is well positioned. The testing and assessment of toxicity and potential risk of chemicals, drug candidates, and medical devices is a requirement for regulatory filings.

Contacts

Axel Sjöblad, CEO, SenzaGen AB

Email: axel.sjoblad@senzagen.com | Mobile: +46 705-35 93 51

Tina Dackemark Lawesson, VP Marketing & Communications

Email: tina.lawesson@senzagen.com | Mobile: +46 708-20 29 44



About us

SenzaGen is a Swedish biotech company that provides state-of-the-art non-animal tests for assessing a substance's allergenicity. The GARD® test method combines genomic data from human cells with machine learning for a unique capability to identify and analyze whether a chemical could cause allergic reactions on the skin or in the respiratory tract. With excellent predictivity, GARD® meets needs in several industries and helps companies develop, produce and deliver safer, ethical and more sustainable products. GARD® tests are performed in SenzaGen's GLP-approved lab and by select partners in Europe and the US. SenzaGen has its headquarters in Lund, Sweden and a subsidiary in the US. For more information, please visit: www.senzagen.com.

SenzaGen is listed on Nasdaq Stockholm First North (ticker: SENZA), and FNCA Sweden AB, +46(0)8-528 00 399, info@fnca.se, is the company's Certified Adviser.

Attachments

[SenzaGen receives SEK 0.65 million order for in vitro skin allergy and irritation tests from global consumer product company](#)